New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:08 EDTTXMDTherapeuticsMD receives enrollment approval for Phase 3 trial of TX 12-001HR
TherapeuticsMD announced that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company’s REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company’s bio-identical combination 17ß-estradiol and progesterone drug candidate, in treating the symptoms of menopause.
News For TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
07:48 EDTTXMDNorth American Menopause Society to hold annual meeting
Subscribe for More Information
October 1, 2015
12:58 EDTTXMDFDA workshop could remove VE black-box warnings, says Jefferies
Subscribe for More Information
September 21, 2015
08:45 EDTTXMDOn The Fly: Pre-market Movers
HIGHER: Atmel (ATML), up 15% after agreeing to be acquired by Dialog Semiconductor in a deal valued at approximately $4.6B, or the equivalent of $10.42 per Atmel share... uniQure (QURE), up 12% after announcing topline results of one-year follow-up data from a Phase I/II clinical trial in four Sanfilippo B syndrome patients... lululemon (LULU), up 3% after the stock was upgraded to Overweight at Morgan Stanley... Alcobra (ADHD), up 15% after announcing that the FDA has granted Fast Track designation to Metadoxine Extended Release for the treatment of Fragile X Syndrome... Denbury Resources (DNR), up 5% after announcing that its board has decided to suspend the company's current 6.25c per share quarterly cash dividend and reinstated the ability for the company to repurchase shares under its previously authorized share repurchase program, which was suspended in late 2014... TherapeuticsMD (TXMD), up 4% after Jefferies analyst Chris Howerton more than doubled his price target for shares to $15 from $7, citing a positive view Vagicap in vulvovaginal atrophy. LOWER: GoPro (GPRO), down 4% after Barron's contended in an article this weekend that the stock may slip another 30% despite its recent pullback... Weatherford (WFT), down 7.7% after announcing the launch of concurrent underwritten public offerings of ordinary shares and mandatory exchangeable subordinated notes for an expected combined amount of $1B... ImmunoGen (IMGN), down 4.7% after Morgan Stanley downgraded the stock to Underweight, stating that consensus estimates for its key asset, IMGN 853, remain too optimistic on the potential success of an upcoming Phase II study.
07:39 EDTTXMDTherapeuticsMD price target raised to $15 from $7 at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use